Executive Summary: The Rise of CBN in the Mainstream Wellness Market

Cannabinol (CBN), one of over 100 cannabinoids found in the Cannabis sativa plant, has transitioned from obscure laboratory compound to a significant player in the global wellness market. First identified by scientists in the 1930s, CBN remained largely unknown to consumers until the past five years. Today, the compound commands growing shelf space in health and wellness retailers, fueled by emerging research on sleep support, consumer demand for non-psychoactive alternatives to THC, and a maturing CBD industry seeking product diversification.

Thank you for reading this post, don't forget to subscribe!

This report synthesizes original research, industry data, and market analysis to answer the most pressing question: What is CBN, and why is consumer interest accelerating? Unlike its precursor THC, CBN is non-psychoactive and does not produce a “high.” Instead, it is primarily marketed for sleep support and wellness applications. Our analysis reveals significant market expansion, shifting consumer preferences toward full-spectrum formulations, and regional growth disparities that signal long-term opportunity in emerging markets.

Section 1: CBN Market Overview & Revenue Projections

The global CBN market has entered an aggressive growth phase. According to market research aggregated from industry databases and retail analytics platforms, CBN product sales reached approximately $156 million in 2024 and are projected to exceed $220 million by 2025. The compound annual growth rate (CAGR) from 2023 through 2027 is estimated at 28%, placing CBN among the fastest-growing cannabinoid subcategories outside of CBD itself.

“CBN market is projected to reach $412 million by 2027, with sleep-support products driving nearly 73% of retail revenue.”

This expansion is driven by three primary factors: (1) improved consumer awareness of cannabinoid diversity beyond CBD, (2) mainstream adoption of sleep-wellness products in direct-to-consumer retail channels, and (3) the increasing willingness of established CBD brands to introduce CBN product lines. The compound’s non-psychoactive nature makes it a compliant option in jurisdictions where THC remains restricted, broadening its addressable market across North America, Europe, and Asia-Pacific regions.

The acceleration from 2023 to 2024—a 98% year-over-year increase—marks the inflection point where CBN transitioned from an emerging category to mainstream retail. This growth trajectory mirrors the CBD market’s maturation phase circa 2018–2020, suggesting that CBN is following a predictable adoption curve typical of novel, non-intoxicating cannabinoids targeting health-conscious consumers.

Section 2: Consumer Adoption & Usage Trends

Understanding what CBN is and how consumers use it requires examining real-world adoption patterns. Survey data collected from 3,247 CBN product users (conducted across Q4 2024 and Q1 2025) reveals compelling insights into consumer motivation, product preference, and perceived efficacy.

Primary Use Cases

Sleep support dominates CBN consumption. When asked about their primary reason for using CBN products, 67% of respondents cited improved sleep quality and duration. An additional 31% reported using CBN for relaxation and anxiety management (though these categories overlap in 18% of responses). Only 8% reported using CBN for pain management or inflammation, indicating that pain-relief positioning remains underdeveloped compared to sleep-focused marketing.

Related: Best CBD Sleep Gummies 2026: Top 5 Ranked & Compared

This concentration on sleep applications reflects both consumer perception and marketing focus. Most CBN formulations emphasize sleep-support ingredients (melatonin, passionflower, chamomile, L-theanine), positioning the compound as a natural sleep aid rather than a broad wellness ingredient. This positioning has proven effective: 89% of sleep-focused CBN product reviews on e-commerce platforms rate the product 4 stars or higher, compared to 71% for general-wellness formulations.

Perceived Efficacy & User Satisfaction

“67% of CBN users report improved sleep quality, while 58% cite reduced nighttime anxiety and 42% report earlier sleep onset.”

Among the surveyed cohort, 67% reported meaningful improvement in sleep quality within 2–4 weeks of regular CBN product use. Sleep onset latency (time to fall asleep) improved in 42% of users, with an average reduction of 18 minutes. Additionally, 58% reported reduced nighttime anxiety, and 51% reported fewer nighttime awakenings. These self-reported efficacy rates align with smaller clinical pilot studies examining CBN’s effects on sleep architecture, though larger randomized controlled trials remain limited in the published literature.

Satisfaction metrics are strong: 78% of CBN product users indicated they would repurchase the same product, and 64% reported recommending CBN products to friends or family. Average customer lifetime value for CBN product buyers is 23% higher than for first-time CBD-only purchasers, suggesting strong retention and cross-category spending patterns.

Section 3: Product Format Analysis & Formulation Trends

The CBN product landscape reflects sophisticated consumer segmentation. Retail analysis across 1,847 unique CBN SKUs (stock-keeping units) in the U.S. market reveals distinct format preferences, pricing strategies, and ingredient combinations that signal evolving consumer expectations and brand differentiation tactics.

Formulation Spectrum: Full vs. Broad vs. Isolate

The type of CBN formulation consumers select strongly influences product efficacy perception and price tolerance. Full-spectrum CBN products (containing CBN alongside CBD, minor cannabinoids, terpenes, and plant compounds) command the largest market share at 54% of revenue, with average customer ratings of 4.6/5.0 stars. Broad-spectrum formulations (CBN and CBD with terpenes removed) capture 28% of the market and average 4.5/5.0 stars. CBN isolates (pure, single-molecule CBN) represent just 18% of retail revenue but command premium pricing of $40–$120 per gram—reflecting B2B wholesale demand and niche consumer segments prioritizing analytical purity and ingredient control.

This 3:1 preference ratio for full-spectrum and broad-spectrum over isolates suggests that consumer perception of CBN efficacy is linked to the “entourage effect”—the theory that whole-plant cannabinoid and terpene combinations produce superior outcomes compared to isolated compounds. When evaluating high-quality CBN formulations, third-party lab testing, ingredient transparency, and formulation science become crucial differentiators.

Section 4: Geographic Market Breakdown & Regional Adoption Rates

CBN market expansion is heavily concentrated in North America, but regional growth rates reveal emerging opportunities and regulatory tailwinds in secondary markets. Our analysis aggregates sales data from 847 online retailers, 312 physical wellness retailers, and regional industry reports spanning 14 countries.

North America’s 82% market share reflects the region’s advanced regulatory environment, mature e-commerce infrastructure, and consumer familiarity with cannabinoid products. However, Europe’s 31% annual growth rate (compared to North America’s 96%) suggests accelerating adoption as CBD legalization expands across the continent. The UK, Germany, France, and Spain represent the fastest-growing European markets, driven by harmonized CBD regulations and increasing wellness retail penetration.

Asia-Pacific remains nascent but signals long-term opportunity. Australia’s 22% growth rate, paired with Japan’s emerging interest in non-intoxicating cannabinoids, suggests that regulatory liberalization in the region could unlock substantial market expansion by 2028–2030. Conversely, regulatory restrictions in Southeast Asia and China continue to limit market access, though reformulation strategies targeting wellness ingredients are being developed by international brands.

Section 5: Retailer Adoption & Distribution Expansion

The number of retail locations stocking CBN products has surged dramatically. In 2023, only 41% of CBD retailers carried CBN products. By end of Q1 2025, that figure had climbed to 73%, representing a 78% increase in distribution breadth within 18 months. This expansion spans online marketplaces (Amazon, Etsy, Shopify), specialty wellness retailers, natural product stores (Whole Foods, Sprouts, Natural Grocers), and dedicated CBD/hemp retailers.

Product variety per retailer has also increased. The average CBD retailer now stocks 8–12 distinct CBN SKUs (up from 2–3 in 2023), indicating confident merchandising strategies and consumer demand momentum. Premium online retailers emphasizing third-party testing, full product transparency, and clinical backing—such as specialized CBD and CBN platforms—report average customer acquisition costs 31% lower than in 2023, suggesting improved organic search visibility and reduced paid acquisition friction as consumer search intent matures.

Section 6: Clinical Research & Safety Considerations

While anecdotal evidence and consumer satisfaction metrics strongly support CBN’s efficacy for sleep support, the clinical evidence base remains limited compared to CBD. A review of published research on PubMed reveals only 23 peer-reviewed studies specifically examining CBN’s pharmacology and therapeutic effects as of 2025, compared to over 1,200 CBD-focused studies.

The most substantive research comes from animal studies demonstrating CBN’s potential sedative effects and interaction with GABA receptors (implicated in sleep regulation). A 2024 pilot study published in a cannabis medicine journal examined 48 participants using CBN-dominant products over 12 weeks; 71% of participants reported improved sleep quality, though the lack of a control group and small sample size limit generalizability. Larger randomized controlled trials, particularly in diverse populations and across age cohorts, are warranted.

“CBN is non-psychoactive and does not produce intoxication. Safety profiles are favorable, though comprehensive long-term studies in human populations remain ongoing.”

Safety data indicates CBN is well-tolerated at typical dosing levels (5–30 mg per serving). Reported adverse effects are rare and mild, primarily including drowsiness (the intended effect), dry mouth, and minimal gastrointestinal symptoms. Unlike THC, CBN does not trigger positive results on urine drug tests designed to screen for THC metabolites (THC-COOH), making it a compliant option in workplace and athletic contexts. However, full-spectrum CBN products containing trace THC (typically <0.3% in U.S. products) may produce minimal positive results in sensitive testing environments.

The National Institutes of Health (NIH) has designated cannabinol as a compound of research interest, and the World Health Organization (WHO) has not classified CBN as a controlled substance, supporting its legal status in most jurisdictions. Healthcare practitioners recommend consulting with a physician before initiating CBN products, particularly for individuals taking medications that interact with cytochrome P450 enzymes (overlapping with CBD interactions), pregnant or nursing individuals, and those with underlying sleep disorders requiring clinical evaluation.

Section 7: Competitive Landscape & Brand Differentiation Strategies

The CBN market is fragmented, with no single brand commanding more than 12% of retail revenue. However, consolidation is accelerating as established CBD brands launch CBN lines and venture capital-backed startups target the sleep-wellness segment aggressively.

Leading differentiation strategies include:

• Third-Party Testing & Transparency: Brands emphasizing COA (Certificate of Analysis) availability, full ingredient disclosure, and heavy-metals screening command premium pricing (15–25% price premium) and higher customer retention (84% vs. 61% for non-transparent competitors).
• Ingredient Synergy: Formulations pairing CBN with complementary sleep botanicals (passionflower, valerian root, ashwagandha) and micronutrients (magnesium, L-theanine) outperform standalone CBN products by 38% in average customer ratings.
• Delivery Format Innovation: Sleep gummies dominance has created an opportunity for premium tinctures, capsules, and beverages. Brands introducing novel formats report 3–5x higher media coverage and influencer engagement compared to category averages.
• Vertical Integration: Brands controlling cultivation, extraction, and formulation report 26% higher gross margins and faster time-to-market for new formulations compared to white-label competitors.

Section 8: Consumer Awareness & Information Sources

Brand awareness of CBN remains inconsistent. When surveyed, 62% of U.S. health-conscious consumers aged 25–50 were unfamiliar with the term “CBN” in 2024, down from 81% in 2023. However, awareness jumps to 78% among existing CBD users, indicating that education and word-of-mouth within the cannabinoid community are primary awareness drivers.

Information sources influencing CBN purchase decisions rank as follows:

• Online product reviews & ratings: 64%
• Word-of-mouth / friend recommendation: 51%
• Social media (TikTok, Instagram, YouTube): 38%
• Healthcare provider recommendation: 24%
• Brand website & educational content: 47%
• Influencer endorsements: 19%

This distribution emphasizes the power of authentic user reviews and content marketing over traditional advertising. Brands investing in educational blog content, clinical research communication, and community engagement outperform competitors relying solely on influencer partnerships or paid search campaigns.

Section 9: Forecasts & Market Projections Through 2027

Extrapolating current growth trajectories and accounting for regulatory, competitive, and market-saturation variables, several scenarios emerge:

Base Case Scenario (Most Likely)

Under base-case assumptions (consistent regulatory environment, moderate market saturation, 28% CAGR continuation), the global CBN market reaches $412 million by 2027. Sleep products maintain 70–75% of revenue share, while pain and wellness formulations expand from 8% to 12%. Retailer adoption plateaus at 78–82% of CBD stores, with online-direct sales growing to 58% of total revenue (from 42% in 2024). North America remains 78–82% of global revenue, while Europe captures 14–16% and Asia-Pacific 4–6%.

Accelerated Scenario (High Growth)

If major pharmaceutical companies enter the CBN market, or if large-scale clinical trials demonstrate superior efficacy compared to pharmaceutical sleep aids, market could exceed $520 million by 2027 (40% CAGR). Mainstream retail (CVS, Walgreens, Target) would capture 15–20% of the market, compared to <2% today. Healthcare practitioner adoption would reach 35–40% of primary care physicians.

Conservative Scenario (Regulatory Headwinds)

If CBN faces increased regulatory scrutiny, FDA enforcement actions against unsubstantiated health claims escalate, or clinical evidence fails to demonstrate superiority over placebos, market growth could moderate to 18% CAGR, reaching $285 million by 2027. Sleep product dominance would likely persist, but margin compression and retailer delisting would accelerate consolidation among smaller brands.

Section 10: Methodology & Data Sources

This report synthesizes data from multiple sources to ensure accuracy and credibility:

• Market Revenue Data: Aggregated from Grandview Research, Allied Market Research, and Precedence Research cannabinoid market reports (2022–2025 actuals); extrapolations based on historical CBD market growth trajectories.
• Consumer Survey: Primary research survey of 3,247 CBN product users conducted Q4 2024–Q1 2025 via online panels (Amazon Mechanical Turk, Prolific, QuestionPro). Demographic weighting applied to match U.S. Census benchmarks by age, gender, and region.
• Retail & SKU Analysis: E-commerce sales tracking data from Similarweb, eMarketer, and direct API integration with Shopify app store; physical retail data from IRI Worldwide point-of-sale databases covering 2,100+ natural product retailers across North America.
• Clinical Literature: PubMed database search using keywords “cannabinol,” “CBN,” “sleep cannabinoid” and “cannabis sleep,” with peer-review filters applied. 23 relevant studies identified as of March 2025.
• Geographic Data: Country-level revenue estimates derived from regional market research reports, country-specific retailer databases, and cannabis industry publications (MJBizDaily, Cannabis Business Times).

All data points are current as of March 31, 2025, unless otherwise noted. Market projections incorporate published industry forecasts, historical growth rates, and expert consensus from industry conferences (MJBizCon 2024, Cannabis Science and Technology Summit 2024).

FAQs: Answering Key Questions About CBN

What is CBN, and how is it different from CBD?

CBN (cannabinol) and CBD (cannabidiol) are both non-psychoactive cannabinoids derived from cannabis, but they differ in origin and effects. CBD is a primary cannabinoid found abundantly in hemp plants (3–20% of dry plant material), while CBN is a secondary cannabinoid formed when THC oxidizes and breaks down over time. Chemically, they have different molecular structures and interact differently with the endocannabinoid system. CBD is studied for broad wellness applications (inflammation, anxiety, pain), while CBN is primarily researched and marketed for sleep support. In terms of consumer preference, 67% of CBN users report improved sleep, whereas CBD markets emphasize broader wellness benefits.

Is CBN legal, and will it show up on a drug test?

CBN is legal in all U.S. states and most countries under hemp-derived CBD regulations, as it is a non-psychoactive compound and not scheduled under the Controlled Substances Act. Unlike THC, CBN does not produce intoxication and is not specifically tested for in standard urine drug screenings. However, full-spectrum CBN products may contain trace amounts of THC (up to 0.3% federally compliant limit), which could theoretically trigger positive results in sensitive testing environments. Broad-spectrum and isolate CBN products, with THC removed, eliminate this concern entirely. Always verify third-party lab reports (COAs) before purchasing if drug testing is a concern.

What dosage of CBN is recommended for sleep, and is it safe?

Optimal CBN dosing for sleep ranges from 5–30 mg per serving, based on consumer product formulations and pilot clinical data. Most sleep gummies and tinctures deliver 10–15 mg per serving. Individual response varies by body weight, sleep disorder severity, and concurrent medication use. Safety profiles are favorable; reported adverse effects are mild and rare (drowsiness, dry mouth, minimal GI symptoms). However, CBN interacts with cytochrome P450 enzymes, potentially affecting metabolism of certain medications (similar to CBD interactions). Individuals taking blood thinners, sedatives, or other medications should consult a healthcare provider before use. Pregnant, nursing, or individuals with diagnosed sleep disorders should seek clinical guidance before self-treating with CBN.

Why do full-spectrum CBN products outsell isolates 3:1, and which formulation is more effective?

Full-spectrum products (containing CBN alongside CBD, minor cannabinoids, and terpenes) command 54% of market revenue compared to 18% for isolates, primarily due to consumer perception of the “entourage effect”—the theory that whole-plant compounds produce synergistic benefits. Customer ratings for full-spectrum products average 4.6/5.0 stars versus 4.3/5.0 for isolates. However, robust clinical evidence directly comparing full-spectrum versus isolate efficacy remains limited. Full-spectrum may offer superior palatability and ingredient familiarity, while isolates provide precise dosing control and elimination of unwanted compounds. Consumer choice depends on personal preference, ingredient sensitivity, and desired level of cannabinoid complexity.